Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
J Drugs Dermatol ; 21(5): 521-522, 2022 May 01.
Article in English | MEDLINE | ID: covidwho-1836609

ABSTRACT

With the onset of the SARS-CoV-2 pandemic, a number of nail unit changes have been associated with SARS-CoV-2 infection. We report a new unique nail finding within one month of infection and RT-PCR test positivity characterized by an abrupt proximal superficial nail plate change characteristic of shoreline nails. The possibility that this nail change may represent a Koebner phenomenon in patients prone to lichen planus is raised. J Drugs Dermatol. 2022;21(5):521-522. doi:10.36849/JDD.2105.


Subject(s)
COVID-19 , Lichen Planus , Nail Diseases , COVID-19/diagnosis , Humans , Lichen Planus/diagnosis , Nail Diseases/diagnosis , Nails , SARS-CoV-2
5.
Biomed Res Int ; 2021: 5595016, 2021.
Article in English | MEDLINE | ID: covidwho-1286757

ABSTRACT

BACKGROUND: COVID-19 is a pandemic disease worldwide. Although cutaneous manifestations may present in affected patients, there have been limited studies on the cutaneous findings and hair and nail abnormalities after discharge. OBJECTIVE: To establish the cutaneous manifestations, hair and scalp disorders, and nail abnormalities in patients who recovered from COVID-19 infections. METHODS: A retrospective chart review and telephone interviews were conducted to determine the cutaneous manifestations, hair and scalp disorders, and nail abnormalities of patients aged over 18 years who were diagnosed with COVID-19 infections at Siriraj Hospital, Bangkok, Thailand, between January and June 2020. RESULTS: Ninety-three patients with prior COVID-19 infections participated in the study. The COVID-19 severity had been mild for most (71%). Cutaneous manifestations were reported in 8 patients (8.6%), with the common skin conditions being maculopapular rash and urticaria. The onsets of the skin conditions were before admission (1%), during admission (4.3%), and after discharge (3.2%). Increased hair shedding was also reported in 22 patients (23.7%), with a female predominance. Three patients were affected during admission, while the others were affected after discharge. The patients with moderate, severe, and critical COVID-19 infections experienced significantly more hair shedding than those with asymptomatic and mild diseases. Only 2 patients with mild COVID-19 disease reported nail abnormalities (chromonychia and brittle nails). CONCLUSIONS: Cutaneous manifestations, hair disorders, and nail abnormalities can occur in patients with COVID-19 after their discharge from hospital. Patients should therefore be followed up in anticipation of dermatological problems.


Subject(s)
COVID-19 , Hair Diseases , Nail Diseases , Pandemics , SARS-CoV-2/metabolism , Adult , Aged , Aged, 80 and over , COVID-19/epidemiology , COVID-19/metabolism , Female , Follow-Up Studies , Hair/metabolism , Hair/virology , Hair Diseases/epidemiology , Hair Diseases/metabolism , Hair Diseases/virology , Humans , Male , Middle Aged , Nail Diseases/epidemiology , Nail Diseases/metabolism , Nail Diseases/virology , Nails/metabolism , Nails/virology , Skin/metabolism , Skin/virology
6.
J Eur Acad Dermatol Venereol ; 35(11): e699-e709, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1269750
8.
18.
Dermatol Ther ; 33(4): e13757, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-526579

ABSTRACT

The novel coronavirus disease 2019 (COVID-19) pandemic has resulted in a paradigm shift in disease management. Since immunosuppression may cause increased susceptibility to COVID-19, there is uncertainty as to whether systemically treated nail psoriasis patients are at increased infection risk. While specific data on nail psoriasis treatments and COVID-19 is lacking, we present clinical trial data on rates of upper respiratory infections, nasopharyngitis, viral infection, pneumonia and overall infections. Some systemic medications and biologics are associated with increased in infections risk compared to placebo in clinical trials. However, this data should be regarded cautiously since clinical trials on nail psoriasis, particularly controlled studies, are lacking. Our recommendations may be helpful in guiding physicians managing nail psoriasis patients during the COVID-19 pandemic.


Subject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Disease Management , Nail Diseases/therapy , Pandemics , Pneumonia, Viral/epidemiology , Practice Guidelines as Topic , Psoriasis/therapy , COVID-19 , Humans , Nail Diseases/epidemiology , Psoriasis/epidemiology , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL